GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04867785

CompletedPhase 2Results posted

A Study of LY3437943 in Participants With Type 2 Diabetes

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Assets

Dulaglutide / Retatrutide

Listed sites

Recruiting sites

—

Enrollment

281

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7-10.5%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04867785

Org study ID17774

Secondary IDJ1I-MC-GZBDEli Lilly and Company

Timeline

Milestones

Study first posted2021-04-30actual

Study start2021-05-13actual

Primary completion2022-07-08actual

Study completion2022-10-27actual

Last update posted2023-07-03actual

Results first posted2023-07-03actual

Assets

Investigational agents

Dulaglutide Retatrutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have Type 2 Diabetes (T2D)

•Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening.

Exclusion criteria

•Have type 1 diabetes mellitus (T1DM)

•Have ketoacidosis

•Have retinopathy, maculopathy

•Have history of pancreatitis

•Have obesity induced by other endocrine disorders

•Have uncontrolled hypertension

•Have acute or chronic hepatitis

•Have chronic kidney disease

•Have an autoimmune abnormality for example, lupus or rheumatoid arthritis

•Have an active or untreated malignancy

Endpoints (20)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Weight & body composition

4 endpoints

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline, 24 Weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
Placebo	-1.86	—
1.5 Milligram (mg) Dulaglutide	-1.16	—
0.5 mg LY3437943	-2.35	—
4 mg LY3437943 (2 mg)	-6.27	—
4 mg LY3437943 (4 mg)	-8.64	—
8 mg LY3437943 (2 mg)	-11.99	—
8 mg LY3437943 (4 mg)	-13.91	—
12 mg LY3437943 (2 mg)	-12.84	—

LSMean Difference-0.4995% CI-2.07 – 1.08p0.540Mixed Models Analysis

LSMean Difference-4.4195% CI-6.69 – -2.13p<0.001Mixed Models Analysis

LSMean Difference-6.7895% CI-9.47 – -4.09p<0.001Mixed Models Analysis

LSMean Difference-10.1395% CI-12.24 – -8.03p<0.001Mixed Models Analysis

LSMean Difference-12.0695% CI-15.06 – -9.06p<0.001Mixed Models Analysis

LSMean Difference-10.9995% CI-13.24 – -8.73p<0.001Mixed Models Analysis

LSMean Difference-1.1995% CI-2.75 – 0.37p0.135Mixed Models Analysis

LSMean Difference-5.1195% CI-7.36 – -2.86p<0.001Mixed Models Analysis

LSMean Difference-7.4895% CI-10.19 – -4.77p<0.001Mixed Models Analysis

LSMean Difference-10.8395% CI-12.89 – -8.77p<0.001Mixed Models Analysis

LSMean Difference-12.7695% CI-15.74 – -9.77p<0.001Mixed Models Analysis

LSMean Difference-11.6995% CI-13.90 – -9.47p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline, 36 Weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
Placebo	-3.28	—
1.5 Milligram (mg) Dulaglutide	-1.97	—
0.5 mg LY3437943	-3.31	—
4 mg LY3437943 (2 mg)	-7.28	—
4 mg LY3437943 (4 mg)	-10.37	—
8 mg LY3437943 (2 mg)	-16.48	—
8 mg LY3437943 (4 mg)	-16.12	—
12 mg LY3437943 (2 mg)	-17.18	—

LSMean Difference-0.0395% CI-2.18 – 2.12p0.979Mixed Models Analysis

LSMean Difference-4.0095% CI-7.32 – -0.68p0.018Mixed Models Analysis

LSMean Difference-7.0995% CI-10.46 – -3.71p<0.001Mixed Models Analysis

LSMean Difference-13.2095% CI-16.74 – -9.66p<0.001Mixed Models Analysis

LSMean Difference-12.8495% CI-16.50 – -9.18p<0.001Mixed Models Analysis

LSMean Difference-13.9195% CI-17.10 – -10.71p<0.001Mixed Models Analysis

LSMean Difference-1.3495% CI-3.45 – 0.77p0.213Mixed Models Analysis

LSMean Difference-5.3195% CI-8.66 – -1.97p0.002Mixed Models Analysis

LSMean Difference-8.4095% CI-11.76 – -5.04p<0.001Mixed Models Analysis

LSMean Difference-14.5195% CI-18.00 – -11.01p<0.001Mixed Models Analysis

LSMean Difference-14.1595% CI-17.77 – -10.54p<0.001Mixed Models Analysis

LSMean Difference-15.2295% CI-18.36 – -12.07p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline, 24 Weeks

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline, 36 Weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

14 endpoints

Primary/registry result

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, 24 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	-0.05	—
1.5 mg Dulaglutide	-1.41	—
0.5 mg LY3437943	-0.43	—
4 mg LY3437943 (2 mg)	-1.39	—
4 mg LY3437943 (4 mg)	-1.30	—
8 mg LY3437943 (2 mg)	-1.99	—
8 mg LY3437943 (4 mg)	-1.88	—
12 mg LY3437943 (2 mg)	-2.01	—

Least Squares (LS) Mean Difference-0.3895% CI-0.94 – 0.18p0.188Mixed Models Analysis

LSMean Difference-1.3495% CI-1.84 – -0.85p<0.001Mixed Models Analysis

LSMean Difference-1.2595% CI-1.85 – -0.65p<0.001Mixed Models Analysis

LSMean Difference-1.9495% CI-2.44 – -1.43p<0.001Mixed Models Analysis

LSMean Difference-1.8395% CI-2.42 – -1.24p<0.001Mixed Models Analysis

LSMean Difference-1.9695% CI-2.43 – -1.50p<0.001Mixed Models Analysis

Primary/protocol endpoint

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, 24 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Change From Baseline in HbA1c

Time frame:Baseline, 24 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	-0.05	—
1.5 Milligram (mg) Dulaglutide	-1.41	—
0.5 mg LY3437943	-0.43	—
4 mg LY3437943 (2 mg)	-1.39	—
4 mg LY3437943 (4 mg)	-1.30	—
8 mg LY3437943 (2 mg)	-1.99	—
8 mg LY3437943 (4 mg)	-1.88	—
12 mg LY3437943 (2 mg)	-2.01	—

LSMean Difference0.9895% CI0.52 – 1.43p<0.001Mixed Models Analysis

LSMean Difference0.0195% CI-0.34 – 0.37p0.935Mixed Models Analysis

LSMean Difference0.1195% CI-0.39 – 0.60p0.668Mixed Models Analysis

LSMean Difference-0.5895% CI-0.95 – -0.21p0.002Mixed Models Analysis

LSMean Difference-0.4795% CI-0.95 – 0.01p0.056Mixed Models Analysis

LSMean Difference-0.6195% CI-0.93 – -0.29p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in HbA1c

Time frame:Baseline, 36 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	-0.30	—
1.5 Milligram (mg) Dulaglutide	-1.36	—
0.5 mg LY3437943	-0.54	—
4 mg LY3437943 (2 mg)	-1.30	—
4 mg LY3437943 (4 mg)	-1.50	—
8 mg LY3437943 (2 mg)	-2.13	—
8 mg LY3437943 (4 mg)	-1.93	—
12 mg LY3437943 (2 mg)	-2.16	—

LSMean Difference-0.2495% CI-0.85 – 0.38p0.448Mixed Models Analysis

LSMean Difference-0.9995% CI-1.60 – -0.38p0.001Mixed Models Analysis

LSMean Difference-1.2095% CI-1.80 – -0.59p<0.001Mixed Models Analysis

LSMean Difference-1.8395% CI-2.41 – -1.24p<0.001Mixed Models Analysis

LSMean Difference-1.6395% CI-2.27 – -0.99p<0.001Mixed Models Analysis

LSMean Difference-1.8595% CI-2.39 – -1.31p<0.001Mixed Models Analysis

LSMean Difference0.8295% CI0.35 – 1.29p<0.001Mixed Models Analysis

LSMean Difference0.0695% CI-0.41 – 0.53p0.796Mixed Models Analysis

LSMean Difference-0.1495% CI-0.61 – 0.32p0.548Mixed Models Analysis

LSMean Difference-0.7795% CI-1.19 – -0.36p<0.001Mixed Models Analysis

LSMean Difference-0.5795% CI-1.08 – -0.07p0.025Mixed Models Analysis

LSMean Difference-0.8095% CI-1.16 – -0.44p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Reaching HbA1c <7.0%

Time frame:Week 24

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	18	—
1.5 Milligram (mg) Dulaglutide	52	—
0.5 mg LY3437943	32	—
4 mg LY3437943 (2 mg)	53	—
4 mg LY3437943 (4 mg)	66	—
8 mg LY3437943 (2 mg)	88	—
8 mg LY3437943 (4 mg)	78	—
12 mg LY3437943 (2 mg)	86	—

Risk Difference (RD)0.1495% CI-0.04 – 0.32p0.121Regression, Logistic

Risk Difference (RD)0.3695% CI0.13 – 0.59p0.002Regression, Logistic

Risk Difference (RD)0.4895% CI0.28 – 0.68p<0.001Regression, Logistic

Risk Difference (RD)0.7095% CI0.53 – 0.87p<0.001Regression, Logistic

Risk Difference (RD)0.6095% CI0.39 – 0.82p<0.001Regression, Logistic

Risk Difference (RD)0.6895% CI0.51 – 0.85p<0.001Regression, Logistic

Risk Difference (RD)-0.2195% CI-0.39 – -0.02p0.030Regression, Logistic

Risk Difference (RD)0.0195% CI-0.22 – 0.24p0.938Regression, Logistic

Risk Difference (RD)0.1395% CI-0.07 – 0.33p0.209Regression, Logistic

Risk Difference (RD)0.3595% CI0.18 – 0.53p<0.001Regression, Logistic

Risk Difference (RD)0.2695% CI0.03 – 0.48p0.024Regression, Logistic

Risk Difference (RD)0.3395% CI0.16 – 0.51p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participant Reaching HbA1c <7.0%

Time frame:Week 36

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	22	—
1.5 Milligram (mg) Dulaglutide	60	—
0.5 mg LY3437943	37	—
4 mg LY3437943 (2 mg)	61	—
4 mg LY3437943 (4 mg)	59	—
8 mg LY3437943 (2 mg)	82	—
8 mg LY3437943 (4 mg)	78	—
12 mg LY3437943 (2 mg)	80	—

Risk Difference (RD)0.1495% CI-0.06 – 0.35p0.169Regression, Logistic

Risk Difference (RD)0.3995% CI0.15 – 0.63p0.001Regression, Logistic

Risk Difference (RD)0.3795% CI0.14 – 0.60p0.002Regression, Logistic

Risk Difference (RD)0.5995% CI0.39 – 0.79p<0.001Regression, Logistic

Risk Difference (RD)0.5695% CI0.34 – 0.78p<0.001Regression, Logistic

Risk Difference (RD)0.5795% CI0.38 – 0.76p<0.001Regression, Logistic

Risk Difference (RD)-0.2395% CI-0.44 – -0.02p0.029Regression, Logistic

Risk Difference (RD)0.0295% CI-0.22 – 0.25p0.898Regression, Logistic

Risk Difference (RD)0.0095% CI-0.24 – 0.23p0.968Regression, Logistic

Risk Difference (RD)0.2295% CI0.02 – 0.42p0.033Regression, Logistic

Risk Difference (RD)0.1995% CI-0.04 – 0.41p0.099Regression, Logistic

Risk Difference (RD)0.2095% CI0.01 – 0.39p0.044Regression, Logistic

Secondary/registry result

Change From Baseline in Fasting Blood Glucose (FBG)

Time frame:Baseline, 24 Weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams/deciliter (mg/dL)	95% CI
Placebo	-10.59	—
1.5 Milligram (mg) Dulaglutide	-46.26	—
0.5 mg LY3437943	-12.71	—
4 mg LY3437943 (2 mg)	-30.19	—
4 mg LY3437943 (4 mg)	-43.89	—
8 mg LY3437943 (2 mg)	-66.09	—
8 mg LY3437943 (4 mg)	-39.80	—
12 mg LY3437943 (2 mg)	-65.20	—

LSMean Difference-2.1295% CI-20.73 – 16.48p0.823Mixed Models Analysis

LSMean Difference-19.6095% CI-47.29 – 8.10p0.165Mixed Models Analysis

LSMean Difference-33.3095% CI-53.56 – -13.04p0.001Mixed Models Analysis

LSMean Difference-55.5095% CI-69.77 – -41.22p<0.001Mixed Models Analysis

LSMean Difference-29.2295% CI-52.84 – -5.59p0.015Mixed Models Analysis

LSMean Difference-54.6195% CI-69.63 – -39.59p<0.001Mixed Models Analysis

LSMean Difference33.5495% CI18.26 – 48.82p<0.001Mixed Models Analysis

LSMean Difference16.0795% CI-10.25 – 42.39p0.231Mixed Models Analysis

LSMean Difference2.3795% CI-16.28 – 21.01p0.804Mixed Models Analysis

LSMean Difference-19.8395% CI-31.01 – -8.65p<0.001Mixed Models Analysis

LSMean Difference6.4595% CI-16.75 – 29.65p0.586Mixed Models Analysis

LSMean Difference-18.9495% CI-30.93 – -6.96p0.002Mixed Models Analysis

Secondary/registry result

Change From Baseline in Fasting Blood Glucose (FBG)

Time frame:Baseline, 36 Weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), mg/dL	95% CI
Placebo	-17.26	—
1.5 Milligram (mg) Dulaglutide	-27.53	—
0.5 mg LY3437943	-17.51	—
4 mg LY3437943 (2 mg)	-21.46	—
4 mg LY3437943 (4 mg)	-38.72	—
8 mg LY3437943 (2 mg)	-69.10	—
8 mg LY3437943 (4 mg)	-41.20	—
12 mg LY3437943 (2 mg)	-67.84	—

LSMean Difference-0.2595% CI-24.57 – 24.07p0.984Mixed Models Analysis

LSMean Difference-4.2095% CI-37.44 – 29.03p0.804Mixed Models Analysis

LSMean Difference-21.4795% CI-51.91 – 8.98p0.167Mixed Models Analysis

LSMean Difference-51.8495% CI-76.09 – -27.59p<0.001Mixed Models Analysis

LSMean Difference-23.9495% CI-57.94 – 10.06p0.168Mixed Models Analysis

LSMean Difference-50.5895% CI-74.94 – -26.22p<0.001Mixed Models Analysis

LSMean Difference10.0295% CI-11.55 – 31.60p0.362Mixed Models Analysis

LSMean Difference6.0795% CI-24.34 – 36.48p0.696Mixed Models Analysis

LSMean Difference-11.1995% CI-39.38 – 16.99p0.436Mixed Models Analysis

LSMean Difference-41.5795% CI-62.89 – -20.25p<0.001Mixed Models Analysis

LSMean Difference-13.6795% CI-46.75 – 19.42p0.418Mixed Models Analysis

LSMean Difference-40.3195% CI-60.77 – -19.85p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in HbA1c

Time frame:Baseline, 24 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in HbA1c

Time frame:Baseline, 36 Weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants Reaching HbA1c <7.0%

Time frame:Week 24

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participant Reaching HbA1c <7.0%

Time frame:Week 36

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Fasting Blood Glucose (FBG)

Time frame:Baseline, 24 Weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change From Baseline in Fasting Blood Glucose (FBG)

Time frame:Baseline, 36 Weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

2 endpoints

Secondary/registry result

Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943

Time frame:Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36

Plasma concentration (steady state)

concentration, descriptive

Posted result

Group	Value (number), nanograms/milliliter (ng/mL)	95% CI
0.5 mg LY3437943	62.8	—
4 mg LY3437943 (2 mg)	466	—
4 mg LY3437943 (4 mg)	551	—
8 mg LY3437943 (2 mg)	1100	—
8 mg LY3437943 (4 mg)	1140	—
12 mg LY3437943 (2 mg)	1620	—

Secondary/protocol endpoint

Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943

Time frame:Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36

Plasma concentration (steady state)

concentration, descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
The lancet. Diabetes & endocrinology2025 Aug (month)PMID40609566doi:10.1016/S2213-8587(25)00092-0via clinicaltrials gov reference derived + pubmed nct search
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (London, England)2023 Aug 12PMID37385280doi:10.1016/S0140-6736(23)01053-Xvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.